Studies in human TET proteases have shown that mutations in TET2 are most relevant to developing hematological malignancies [32,33,34] and are also associated with increased risks of autoimmunity in myelodysplastic syndrome patients [35]. This evidence concerns the gene TET2 and hematologic disorder.